促肝细胞生长素肠溶胶囊对初治肺结核患者药物肝损伤的临床分析  

Clinical Analysis of Liver Injury with Hepatocellular Growth Receptor Enteric-coated Capsules in Newly Treated Pulmonary Tuberculosis Patients

作　　者：曹仕鹏[1] 李春香[1] 李爱美[1] 谢和宾[1] CAO Shi-peng;LI Chun-xiang;LI Ai-mei;XIE He-bin(Pulmonary hospital No.3 ward,Changsha central hospital,Hunan Changsha 410004,China)

机构地区：[1]长沙市中心医院肺科医院三病室,湖南长沙410004

出　　处：《临床医药文献电子杂志》2018年第51期17-19,共3页Electronic Journal of Clinical Medical Literature

基　　金：国家"十二五"科技重大专项(2013ZX10005004)

摘　　要：目的评价促肝细胞生长素肠溶胶囊对初治肺结核患者药物肝损伤的临床疗效和安全性。方法将本院进行抗结核化疗前肝功能正常的140例初治肺结核(PPTB)患者,按照治疗方法的不同分为观察组(促肝细胞生长素肠溶胶囊保肝治疗)和对照组(葡醛内酯片保肝治疗),对两组患者不同时期肝损伤率、总肝损伤率、肝损伤程度、促肝细胞生长素肠溶胶囊使用的安全性进行观察。结果观察组患者在标准抗结核化疗4周内肝损伤率、5~8周肝损伤率、总肝损伤率均低于对照组,P<0.05;对照组发生轻度、中度、重度肝损伤的构成比都明显高于观察组,P<0.05;观察组患者未出现不适症状或毒副作用。结论促肝细胞生长素肠溶胶囊可以明显降低PPTB患者ATDILI的发生率,减轻肝损伤程度,使用安全性高。Objective To evaluate the clinical efficacy and safety of hepatocyte growth-promoting entericcoated capsules for drug-induced liver injury in newly treated patients with pulmonary tuberculosis.Methods 140 cases of newly diagnosed pulmonary tuberculosis(PPTB)patients with normal liver function before anti-tuberculosis chemotherapy were divided into observation group(hepatocyte growth-promoting enteric-coated capsules for hepatoprotective treatment)and control group(glucoaldehyde).Lactone tablets for hepatoprotective treatment)The liver injury rate,the total liver injury rate,the degree of hepatic damage,and the safety of hepatocyte growth-promoting enteric-coated capsules were observed in both groups at different stages.Results In the observation group,the rate of hepatic injury,the rate of hepatic damage during 5 to 8 weeks,and the total hepatic injury rate were lower in the observation group than in the control group,P<0.05;the constituent ratios of mild,moderate,and severe liver injury in the control group were significantly higher than the observation group,P<0.05;Patients in the observation group did not show symptoms of discomfort or side effects.Conclusion Hepatocyte growth-promoting enteric-coated capsules can significantly reduce the incidence of ATDILI in PPTB patients,reduce the degree of liver injury,and have high safety in use.

关 键 词：肺结核 药物性肝损伤 促肝细胞生长素肠溶胶囊 

分 类 号：R521[医药卫生—内科学]